New Elite Feature: Screen & Chart at the same time

Cadrenal Therapeutics Inc.

Contributing Author

Recent Articles by Cadrenal Therapeutics Inc.

May-19	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 CVKD GlobeNewswire
May-07	Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA CVKD GlobeNewswire
Apr-30	Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) CVKD +19.32% GlobeNewswire
Mar-31	Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting CVKD +20.47% GlobeNewswire
Mar-12	Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes CVKD -7.95% GlobeNewswire
Mar-02	Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion CVKD GlobeNewswire
Feb-24	Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement CVKD +16.10% GlobeNewswire
Jan-12	Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor CVKD GlobeNewswire
Dec-17	Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 CVKD GlobeNewswire
Dec-11	Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) CVKD GlobeNewswire
Dec-01	Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors CVKD GlobeNewswire
Nov-19	Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award CVKD -5.61% GlobeNewswire
Nov-10	Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update CVKD GlobeNewswire
Sep-29	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 CVKD GlobeNewswire
Sep-15	Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors CVKD GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)